Publication

Article

CURE

Spring 2009
Volume8
Issue 1

Q&A: KRAS Testing

Gene testing now recommended before colon cancer treatment

Q: Should I be tested for the KRAS mutation before beginning colorectal cancer treatment?

Recent research confirmed that the mutation status of the KRAS gene in colon cancer patients can determine if the tumor will respond to therapies that inhibit the epidermal growth factor receptor. If the mutation is present, there is little to no likelihood the patient will respond to Erbitux (cetuximab) or Vectibix (panitumumab), the two drugs affected by the new research. If it is not present, the chances for a response are better, though not guaranteed.

In January, the American Society of Clinical Oncology recommended all advanced colorectal cancer patients undergo testing to determine if the mutation is present before receiving treatment.

We have made progress in treating advanced cancer during the past 30 years by developing new drugs and treatment regimens. Most notably, by using our understanding of what drives cancer cell growth, targeted therapies have been developed to attack malignant cells instead of normal cells. Targeted therapies are expensive, can cause side effects, and don’t work for everyone, but now with the identification of the KRAS gene we have a way to predict—with a reasonable degree of accuracy—which colorectal cancer patients would benefit from Erbitux or Vectibix and which patients should receive other treatments.

As we move forward in the era of individualized medicine, we can look forward to the day when the genetic makeup of each person’s cancer will be analyzed, revealing the appropriate targeted therapy to treat the disease. This will lead to better responses and tumor control, hopefully with fewer side effects and possibly lower health care costs, which in turn will mean greater access to these drugs for the patients who need them.

Read more about KRAS and colorectal cancer in “Bittersweet Gene” from the Winter 2008 issue, available at www.curetoday.com/bittersweet_gene.

—Len Lichtenfeld, MD, is deputy medical officer for the American Cancer Society

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
Image of two doctors with text.
Imiage of two doctors with text.
Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.
Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer.
Image of woman.
Image of Dr. Eng.
Related Content